Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
24 Oct 2023
Historique:
received: 29 09 2023
revised: 13 10 2023
accepted: 13 10 2023
medline: 15 11 2023
pubmed: 14 11 2023
entrez: 14 11 2023
Statut: epublish

Résumé

Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most challenging malignancies to treat, with a complex interplay of molecular pathways contributing to its aggressive nature. Galectin-1 (Gal-1), a member of the galectin family, has emerged as a pivotal player in the PDAC microenvironment, influencing various aspects from tumor growth and angiogenesis to immune modulation. This review provides a comprehensive overview of the multifaceted role of Galectin-1 in PDAC. We delve into its contributions to tumor stroma remodeling, angiogenesis, metabolic reprogramming, and potential implications for therapeutic interventions. The challenges associated with targeting Gal-1 are discussed, given its pleiotropic functions and complexities in different cellular conditions. Additionally, the promising prospects of Gal-1 inhibition, including the utilization of nanotechnology and theranostics, are highlighted. By integrating recent findings and shedding light on the intricacies of Gal-1's involvement in PDAC, this review aims to provide insights that could guide future research and therapeutic strategies.

Identifiants

pubmed: 37958483
pii: ijms242115500
doi: 10.3390/ijms242115500
pmc: PMC10650903
pii:
doi:

Substances chimiques

Galectin 1 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
ID : JP15/19

Références

Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572947
J Med Biochem. 2022 Feb 2;41(1):79-90
pubmed: 35611243
Mol Cancer. 2018 Feb 19;17(1):62
pubmed: 29458370
J Pharm Biomed Anal. 2020 Jul 15;186:113300
pubmed: 32413824
Integr Cancer Ther. 2018 Dec;17(4):1016-1019
pubmed: 30136592
Cancers (Basel). 2021 Dec 06;13(23):
pubmed: 34885243
Int J Mol Sci. 2016 Jun 03;17(6):
pubmed: 27271610
Immunol Rev. 2019 Jan;287(1):202-225
pubmed: 30565241
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
JAMA. 2021 Sep 7;326(9):851-862
pubmed: 34547082
Hum Vaccin Immunother. 2014;10(11):3354-68
pubmed: 25483688
Int J Cancer. 2012 May 15;130(10):2337-48
pubmed: 21780106
Int J Mol Sci. 2021 Dec 14;22(24):
pubmed: 34948209
Cancer Lett. 2017 Jul 1;397:43-51
pubmed: 28336327
J Cell Biochem. 2007 Jul 1;101(4):887-907
pubmed: 17266048
Biomolecules. 2021 Sep 20;11(9):
pubmed: 34572599
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Glycobiology. 2014 Oct;24(10):921-5
pubmed: 24973253
Cancer Immunol Immunother. 2018 Dec;67(12):1815-1823
pubmed: 30167864
Oncol Rep. 2020 Oct;44(4):1322-1332
pubmed: 32945517
Biomolecules. 2021 Aug 07;11(8):
pubmed: 34439836
J Pathol. 2018 Nov;246(3):311-322
pubmed: 30027561
EBioMedicine. 2020 Mar;53:102662
pubmed: 32139180
Cancers (Basel). 2023 May 26;15(11):
pubmed: 37296886
Cell Commun Signal. 2018 Sep 4;16(1):54
pubmed: 30180849
Int J Mol Sci. 2021 Dec 23;23(1):
pubmed: 35008569
Cancer Cell Int. 2018 Jun 18;18:85
pubmed: 29946224
Front Oncol. 2019 Nov 01;9:1143
pubmed: 31737570
Nat Commun. 2015 May 18;6:7158
pubmed: 25981357
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cell Death Dis. 2010;1:e23
pubmed: 21364631
Cancer Discov. 2023 Feb 6;13(2):278-297
pubmed: 36622087
Front Oncol. 2021 Mar 29;11:626577
pubmed: 33854965
Cancer Cell Int. 2019 Nov 21;19:309
pubmed: 31832021
Cancers (Basel). 2021 Nov 03;13(21):
pubmed: 34771675
Breast Cancer Res. 2001;3(5):323-7
pubmed: 11597322
Front Chem. 2019 Dec 03;7:823
pubmed: 31850312
Front Oncol. 2021 Jan 14;10:621937
pubmed: 33520728
J Immunol. 1998 Jun 15;160(12):6151-8
pubmed: 9637533
PLoS One. 2013 Dec 23;8(12):e84934
pubmed: 24376856
Cancer Treat Rev. 2014 Mar;40(2):307-19
pubmed: 23953240
Front Immunol. 2023 Feb 03;14:1145268
pubmed: 36817445
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Tumour Biol. 2015 Jul;36(7):5617-26
pubmed: 25725585
J Immunol. 2009 Jun 1;182(11):7001-8
pubmed: 19454697
Oncotarget. 2018 Aug 31;9(68):32984-32996
pubmed: 30250644
World J Clin Cases. 2021 May 6;9(13):2969-2982
pubmed: 33969083
Mol Cancer Ther. 2017 Jul;16(7):1212-1223
pubmed: 28396365
Oncotarget. 2017 Sep 23;8(49):86488-86502
pubmed: 29156810
PLoS One. 2014 Mar 04;9(3):e90476
pubmed: 24595374
Acta Diabetol. 2016 Dec;53(6):945-956
pubmed: 27552832
Mol Ther Oncolytics. 2019 Nov 29;16:41-52
pubmed: 31930165
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
BMC Cancer. 2014 Oct 02;14:738
pubmed: 25274283
Front Cell Dev Biol. 2020 Aug 06;8:760
pubmed: 32850862
Cancer Res. 2004 Dec 15;64(24):9018-26
pubmed: 15604267
Biochim Biophys Acta Gen Subj. 2018 Jul;1862(7):1537-1546
pubmed: 29477748
World J Gastroenterol. 2022 Jul 21;28(27):3297-3313
pubmed: 36158269
Cancer Biol Ther. 2012 Aug;13(10):899-907
pubmed: 22785208
Front Cell Dev Biol. 2021 Jan 11;8:607209
pubmed: 33505964
Cancer Cell. 2012 Jun 12;21(6):822-35
pubmed: 22698406
Cancers (Basel). 2021 Jun 08;13(12):
pubmed: 34201127
Glycobiology. 2006 Nov;16(11):137R-157R
pubmed: 16840800
Blood. 2007 Oct 15;110(8):2819-27
pubmed: 17591944
J Acad Nutr Diet. 2018 Apr;118(4):555-567
pubmed: 28919082
Front Cell Dev Biol. 2021 Nov 25;9:787485
pubmed: 34901028
Nat Immunol. 2012 Dec;13(12):1129-32
pubmed: 23160205
Cancers (Basel). 2019 Oct 24;11(11):
pubmed: 31652904
Cancers (Basel). 2022 May 24;14(11):
pubmed: 35681557
Front Immunol. 2020 Jan 22;10:3070
pubmed: 32038621
Cells. 2021 Jun 07;10(6):
pubmed: 34200375
Cancers (Basel). 2022 Jul 05;14(13):
pubmed: 35805064
Cancer Lett. 2012 Sep 28;322(2):169-76
pubmed: 22450749
Nat Immunol. 2009 Sep;10(9):981-91
pubmed: 19668220
Oncogene. 2019 Mar;38(13):2223-2240
pubmed: 30487597
Cancer Metastasis Rev. 2012 Dec;31(3-4):763-78
pubmed: 22706847
World J Gastroenterol. 2017 Aug 7;23(29):5266-5281
pubmed: 28839427
Front Immunol. 2019 Aug 07;10:1762
pubmed: 31440233
Cancers (Basel). 2021 Jul 07;13(14):
pubmed: 34298625
J Biol Chem. 2005 Feb 25;280(8):6969-85
pubmed: 15556941
Front Immunol. 2022 Jul 22;13:925985
pubmed: 35936003
Cancer Res. 2010 Aug 1;70(15):6216-24
pubmed: 20647324
Cell Signal. 2006 Nov;18(11):1887-96
pubmed: 16549336
J Cancer. 2020 Jan 14;11(6):1505-1515
pubmed: 32047557
World J Gastrointest Oncol. 2020 Feb 15;12(2):173-181
pubmed: 32104548
Clin Cancer Res. 2015 Apr 15;21(8):1944-50
pubmed: 25623214
Cells. 2022 Sep 29;11(19):
pubmed: 36231030
J Biol Chem. 2016 Oct 21;291(43):22630-22637
pubmed: 27587395
Gastroenterology. 2009 Apr;136(4):1379-90, e1-5
pubmed: 19171142
Chin Clin Oncol. 2017 Dec;6(6):66
pubmed: 29156888
Biomolecules. 2023 May 29;13(6):
pubmed: 37371482
Curr Oncol. 2023 Mar 30;30(4):3871-3885
pubmed: 37185406
J Immunol. 2001 Nov 15;167(10):5697-707
pubmed: 11698442
Br J Cancer. 2005 Apr 11;92(7):1188-92
pubmed: 15785741
FEBS J. 2007 Jul;274(13):3233-56
pubmed: 17535296
J Histochem Cytochem. 2001 Apr;49(4):539-49
pubmed: 11259457
PLoS One. 2022 Jan 12;17(1):e0262439
pubmed: 35020761
J Clin Med. 2023 Jun 27;12(13):
pubmed: 37445352
Biomolecules. 2023 Oct 10;13(10):
pubmed: 37892182
Cancers (Basel). 2019 Mar 18;11(3):
pubmed: 30889903
Front Immunol. 2023 Jan 10;13:1104625
pubmed: 36703969
Front Cardiovasc Med. 2023 Feb 17;10:1052959
pubmed: 36873388
ANZ J Surg. 2008 Apr;78(4):245-51
pubmed: 18366394
J Biol Chem. 1992 May 25;267(15):10342-7
pubmed: 1587821
Cancer Cell. 2012 Jun 12;21(6):836-47
pubmed: 22698407
Oncoimmunology. 2014 Aug 03;3(8):e952201
pubmed: 25610742
Cancers (Basel). 2022 Aug 31;14(17):
pubmed: 36077772
Front Immunol. 2020 Jul 22;11:1371
pubmed: 32793192
Lab Invest. 2000 Aug;80(8):1233-41
pubmed: 10950114
Int J Mol Sci. 2017 Jun 22;18(7):
pubmed: 28640192
J Investig Med. 2012 Apr;60(4):643-63
pubmed: 22406516
Sci Rep. 2022 Jan 24;12(1):1272
pubmed: 35075140
Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3769-E3778
pubmed: 29615514
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Front Oncol. 2021 Sep 03;11:714598
pubmed: 34540683
J Exp Clin Cancer Res. 2021 Jan 9;40(1):25
pubmed: 33422093
Oncol Rep. 2018 Mar;39(3):1347-1355
pubmed: 29328490
J BUON. 2016 Jul-Aug;21(4):941-949
pubmed: 27685917
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
FEBS J. 2010 Sep;277(17):3552-63
pubmed: 20695889
Int J Mol Sci. 2022 Jan 16;23(2):
pubmed: 35055153
Diagnostics (Basel). 2021 Mar 20;11(3):
pubmed: 33804776
Signal Transduct Target Ther. 2021 Jul 5;6(1):249
pubmed: 34219130
Exp Biol Med (Maywood). 2016 May;241(10):1074-83
pubmed: 27229902
Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G729-36
pubmed: 16373424
Cancers (Basel). 2022 Sep 21;14(19):
pubmed: 36230505
J Immunol. 2000 Sep 1;165(5):2331-4
pubmed: 10946254
Cancers (Basel). 2022 Nov 08;14(22):
pubmed: 36428567
Cells. 2020 Mar 11;9(3):
pubmed: 32168866
J Clin Oncol. 2018 Aug 20;36(24):2545-2556
pubmed: 29791286
Int J Mol Sci. 2023 Mar 30;24(7):
pubmed: 37047471
Cells. 2023 May 29;12(11):
pubmed: 37296616
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32752017
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229669
Gut. 2003 Feb;52(2):275-82
pubmed: 12524413
Cells. 2022 Sep 21;11(19):
pubmed: 36230914
Biomolecules. 2021 Sep 23;11(10):
pubmed: 34680031
Cell Signal. 2005 Oct;17(10):1240-7
pubmed: 16038798
Oncoimmunology. 2020 Jul 16;9(1):1794359
pubmed: 32923157
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Pancreas. 2011 Aug;40(6):832-9
pubmed: 21747316
Biophys J. 2016 May 10;110(9):2106-19
pubmed: 27166818
Int J Mol Sci. 2016 Sep 16;17(9):
pubmed: 27649167
Int J Mol Sci. 2019 Feb 05;20(3):
pubmed: 30764482
J Cell Sci. 2018 May 1;131(9):
pubmed: 29717004
Clin Immunol. 2012 Feb;142(2):107-16
pubmed: 22019770
Clin Transl Med. 2015 Feb 26;4:6
pubmed: 25852822
Cancer Res. 2014 Jul 1;74(13):3512-24
pubmed: 24812270
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Oncotarget. 2016 Aug 2;7(31):50735-50754
pubmed: 27191744
Front Oncol. 2022 Jul 28;12:951019
pubmed: 35965504
Cancers (Basel). 2021 Sep 09;13(18):
pubmed: 34572756
Diabetes. 2017 Nov;66(11):2830-2839
pubmed: 28705881
Int J Mol Sci. 2022 May 16;23(10):
pubmed: 35628357
FEBS J. 2012 Nov;279(21):4062-80
pubmed: 22943525
J Exp Clin Cancer Res. 2019 May 14;38(1):192
pubmed: 31088566
Cancers (Basel). 2021 Aug 17;13(16):
pubmed: 34439292
Front Immunol. 2019 Apr 09;10:496
pubmed: 31024520
J Adv Pract Oncol. 2020 Sep-Oct;11(7):693-698
pubmed: 33575066

Auteurs

Ana Bogut (A)

City Medical Emergency Department, 11000 Belgrade, Serbia.

Bojan Stojanovic (B)

Department of Surgery, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Department of General Surgery, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia.

Marina Jovanovic (M)

Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

Milica Dimitrijevic Stojanovic (M)

Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

Nevena Gajovic (N)

Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

Bojana S Stojanovic (BS)

Department of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

Goran Balovic (G)

Department of Surgery, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

Milan Jovanovic (M)

Department of Abdominal Surgery, Military Medical Academy, 11000 Belgrade, Serbia.

Aleksandar Lazovic (A)

Department of General Surgery, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia.

Milos Mirovic (M)

Department of Surgery, General Hospital of Kotor, 85330 Kotor, Montenegro.

Milena Jurisevic (M)

Department of Clinical Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

Ivan Jovanovic (I)

Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

Violeta Mladenovic (V)

Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH